Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) COO Anish Patel sold 716 shares of the company’s stock in a transaction on Friday, October 18th. The shares were sold at an average price of $30.00, for a total transaction of $21,480.00. Following the completion of the transaction, the chief operating officer now owns 343,311 shares in the company, valued at approximately $10,299,330. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Enliven Therapeutics Price Performance
ELVN stock opened at $28.98 on Friday. The business’s fifty day moving average price is $24.62 and its two-hundred day moving average price is $22.93. The stock has a market capitalization of $1.36 billion, a price-to-earnings ratio of -15.02 and a beta of 1.10. Enliven Therapeutics, Inc. has a fifty-two week low of $9.80 and a fifty-two week high of $30.03.
Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.17. Research analysts expect that Enliven Therapeutics, Inc. will post -1.98 EPS for the current year.
Hedge Funds Weigh In On Enliven Therapeutics
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a “buy” rating and issued a $37.00 price target on shares of Enliven Therapeutics in a research note on Tuesday, October 1st.
Get Our Latest Report on Enliven Therapeutics
Enliven Therapeutics Company Profile
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Further Reading
- Five stocks we like better than Enliven Therapeutics
- What is a support level?
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Financial Services Stocks Investing
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- How to Calculate Return on Investment (ROI)
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.